罗西维林片联合缩泉胶囊治疗膀胱过度活动症的临床观察
라서유림편연합축천효낭치료방광과도활동증적림상관찰
Efficacy and safety of combining rociverine tablets with Suoquan capsule in treatment of overactive bladder
  • 万方数据
    中国医药 중국의약
    CHINA MEDICINE
    2014年 12期 1790-1793 ,共4页

    刘成%穆家贵%刘多%刘雪军%任艳胜%朱东生

    류성%목가귀%류다%류설군%임염성%주동생

    膀胱过度活动症%罗西维林%缩泉胶囊 膀胱過度活動癥%囉西維林%縮泉膠囊
    방광과도활동증%라서유림%축천효낭
    Overactive bladder%Rociverine%Suoquan capsule
    目的 探讨罗西维林片联合缩泉胶囊治疗膀胱过度活动症(OAB)的临床疗效及安全性.方法 收集2011年10月至2013年10月期间OAB患者126例,采用完全随机方法将患者分为4组:A组(34例,缩泉胶囊1.8g,3次/d+罗西维林片10 mg,3次/d),B组(32例,罗西维林片10 mg,3次/d),C组(32例,缩泉胶囊1.8g,3次/d),D组(28例,仅给予膀胱训练指导),疗程均为4周.所有患者都给予膀胱训练指导.观察各组治疗前后的主观指标膀胱过度活动症症状评分(OABSS)及客观指标24 h排尿次数、尿急次数、尿失禁次数、夜尿次数、每次排尿量的变化,评估治疗后患者OAB症状的改善情况及安全性.结果 治疗前后OABSS评分、24 h排尿次数、尿急次数、夜尿次数、尿失禁次数、平均每次排尿量A组分别为(9.5±2.1)和(2.4±1.0)分,(13.6±3.8)和(7.2±1.3)次,(7.7±2.7)和(2.4±1.2)次,(4.1±2.1)和(1.0±0.3)次,(3.5±1.4)和(0.8±0.3)次,(124±28)和(280±36) ml;B组分别为(9.7±1.8)和(5.4±1.9)分,(13.9±3.6)和(8.8±1.4)次,(7.6±2.5)和(4.4±1.4)次,(4.2±1.8)和(1.8±0.4)次,(3.6±1.3)和(1.6±0.4)次,(122±29)和(210±38) ml;C组分别为(9.6±2.0)和(5.3±1.8)分,(13.8±3.7)和(8.7±1.2)次,(7.7±2.4)和(4.3±1.3)次,(4.3±2.1)和(1.7±0.5)次,(3.6±1.5)和(2.0±0.2)次,(124±27)和(212±36) ml;D组分别为(9.2±1.9)和(8.4±1.8)分,(13.5±3.4)和(11.2±2.2)分,(7.6±2.6)和(6.4±2.1)分,(4.3±2.0)和(3.3±0.4)分,(3.5±1.3)和(2.8±0.3)次,(125 ±28)和(161±38) ml;4组治疗前后组内对比,主观指标及客观指标差异均有统计学意义(均P＜0.05).A组、B组、C组治疗后各项指标与D组比较,差异均有统计学意义(均P＜0.05).A组与B组、C组之间比较,差异均有统计学意义(P＜0.05).总的不良反应发生率A组为8.8％ (3/34),B组为21.8％(7/32),C组为9.3％ (3/32),A组与B组之间差异有统计学意义(P＜0.05),A组与C组之间比较,差异无统计学意义(P＞0.05).4组患者均无严重不良事件发生.结论 罗西维林片联合缩泉胶囊治疗膀胱过度活动症疗效较好,安全可靠.
    목적 탐토라서유림편연합축천효낭치료방광과도활동증(OAB)적림상료효급안전성.방법 수집2011년10월지2013년10월기간OAB환자126례,채용완전수궤방법장환자분위4조:A조(34례,축천효낭1.8g,3차/d+라서유림편10 mg,3차/d),B조(32례,라서유림편10 mg,3차/d),C조(32례,축천효낭1.8g,3차/d),D조(28례,부급여방광훈련지도),료정균위4주.소유환자도급여방광훈련지도.관찰각조치료전후적주관지표방광과도활동증증상평분(OABSS)급객관지표24 h배뇨차수、뇨급차수、뇨실금차수、야뇨차수、매차배뇨량적변화,평고치료후환자OAB증상적개선정황급안전성.결과 치료전후OABSS평분、24 h배뇨차수、뇨급차수、야뇨차수、뇨실금차수、평균매차배뇨량A조분별위(9.5±2.1)화(2.4±1.0)분,(13.6±3.8)화(7.2±1.3)차,(7.7±2.7)화(2.4±1.2)차,(4.1±2.1)화(1.0±0.3)차,(3.5±1.4)화(0.8±0.3)차,(124±28)화(280±36) ml;B조분별위(9.7±1.8)화(5.4±1.9)분,(13.9±3.6)화(8.8±1.4)차,(7.6±2.5)화(4.4±1.4)차,(4.2±1.8)화(1.8±0.4)차,(3.6±1.3)화(1.6±0.4)차,(122±29)화(210±38) ml;C조분별위(9.6±2.0)화(5.3±1.8)분,(13.8±3.7)화(8.7±1.2)차,(7.7±2.4)화(4.3±1.3)차,(4.3±2.1)화(1.7±0.5)차,(3.6±1.5)화(2.0±0.2)차,(124±27)화(212±36) ml;D조분별위(9.2±1.9)화(8.4±1.8)분,(13.5±3.4)화(11.2±2.2)분,(7.6±2.6)화(6.4±2.1)분,(4.3±2.0)화(3.3±0.4)분,(3.5±1.3)화(2.8±0.3)차,(125 ±28)화(161±38) ml;4조치료전후조내대비,주관지표급객관지표차이균유통계학의의(균P＜0.05).A조、B조、C조치료후각항지표여D조비교,차이균유통계학의의(균P＜0.05).A조여B조、C조지간비교,차이균유통계학의의(P＜0.05).총적불량반응발생솔A조위8.8％ (3/34),B조위21.8％(7/32),C조위9.3％ (3/32),A조여B조지간차이유통계학의의(P＜0.05),A조여C조지간비교,차이무통계학의의(P＞0.05).4조환자균무엄중불량사건발생.결론 라서유림편연합축천효낭치료방광과도활동증료효교호,안전가고.
    Objective To assess the efficacy and safety of combining Rociverine Tablets with Suoquan capsule in treatment of patients with overactive bladder(OAB).Methods Totally 126 cases of overactive bladder were collected to research and were randomly divided into four groups.Patients in A group were administrated with Rociverine Tablets at 10mg and Suoquan capsule at 1.8g three times a day for 4 weeks.Patients in B group were administrated only with Rociverine Tablets for 4 weeks.Patients in C group were administrated only with Suoquan capsule for 4 weeks.All patients had the bladder training.The efficacy and safety of treatment were assessed before and after treatment in the subjective outcome measure of OABSS and the objective outcome measures including daily frequency of micturition,urgency,urgency incontinence,nocturia and avoiding volumes.Results The subjective outcome measure and objective outcome measures in the A group before-and after-treatment:(9.5 ± 2.1)and (2.4 ± 1.0) for OABSS,(13.6 ± 3.8) and (7.2 ± 1.3) for frequency of micturition,(7.7 ± 2.7) and (2.4 ± 1.2) for frequency of urgency,(3.5 ± 1.4) and (0.8 ± 0.3) for frequency of nocturia,(4.1 ± 2.1) and (1.0 ± 0.3)for frequency of urgency incontinence,(124 ± 28) and (280 ± 36) ml for voiding volumes.These data in the B group were(9.7 ± 1.8)and(5.4± 1.9),(13.9 ±3.6)and(8.8 ± 1.4),(7.6±2.5)and(4.4 ± 1.4),(4.2 ± 1.8)and (1.8 ±0.4),(3.6± 1.3)and(1.6 ±0.4),(122 ±29)and(210 ±38).These in the C group were (9.6 ±2.0) and (5.3 ±1.8),(13.8 ±3.7) and (8.7±1.2),(7.7±2.4) and (4.3±1.3),(4.3±2.1) and (1.7 ± 0.5),(3.6±1.5)and(2.0±0.2),(124±27)and(212±36).These in the D group were (9.2±1.9) and (8.4 ±1.8),(13.5 ±3.4) and (11.2 ±2.2),(7.6 ±2.6) and (6.4±2.1),(4.3 ±2.0) and (3.3 ±0.4),(3.5 ± 1.3) and (2.8 ± 0.3),(125 ± 28) and(161 ± 38).There wre significant differences in subjective and objective outcome measures of patients in each group before and after treatment (P ＜ 0.05).Moreover,compared with D groups,A,B and C groups all had significant differences in subjective and Objective outcome measures of patients at the end of treatments(P ＜ 0.05).There were significant differences in subjective and Objective outcome measures of patients between A and B groups.The incidences of adverse events of A,B and C groups were 8.8％ (3/34),21.8％ (7/32) and 9.3％ (3/32) respectively.There were significant differences in the incidences of adverse events between A group and B group (P ＜ 0.05).There were no significant differences in the incidences of adverse events between A group and C group (P ＞ 0.05).No severe adverse events happened in four groups.Conclusion Combining Rociverine Tablets with Suoquan capsule in treatment of patients with overactive bladder can significantly improve the clinical efficiency.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문